IJID Regions is a pioneering open access journal published by Elsevier, focusing on the critical fields of epidemiology, infectious diseases, and public health. Established in 2021, the journal aims to provide a platform for disseminating high-quality, innovative research that addresses pressing health issues and informs evidence-based practices in communities around the globe. With its impact factors reflecting a Tier Q2 and Q3 ranking in various medical subcategories on the Scopus platform, IJID Regions is positioned as a valuable resource for researchers, health professionals, and policy-makers striving to enhance public health outcomes. This journal not only champions open access since its inception, promoting the free flow of information, but also welcomes contributions that shed light on contemporary challenges in environmental and occupational health. Its commitment to fostering dialogue and collaboration in the health sciences is paramount, making it an essential read for those engaged in advancing public health knowledge and initiatives.

LANCET INFECTIOUS DISEASES is a premier journal published by Elsevier Science Ltd, dedicated to disseminating high-quality research and comprehensive reviews in the field of infectious diseases. Since its inception in 2001, the journal has become a pivotal resource in the medical community, recognized for its rigorous peer-review process and impactful contributions to public health. With an impressive Scopus rank of #2 out of 344 in the category of Medicine - Infectious Diseases, it consistently ranks in the 99th percentile, highlighting its importance and influence in shaping clinical and epidemiological research. The journal's commitment to advancing knowledge in infectious diseases is underscored by its Q1 quartile designation in 2023, affirming its status as a leading academic outlet. Although not an open-access journal, LANCET INFECTIOUS DISEASES provides essential insights for researchers, healthcare professionals, and students, bridging the gap between cutting-edge research and practical application in an increasingly interconnected world.

Infectious Diseases Now is a premier academic journal dedicated to the evolving field of infectious diseases, published by Elsevier France - Éditions Scientifiques Médicales Elsevier. With an ISSN of 2666-9927 and an E-ISSN of 2666-9919, this journal stands at the forefront of disseminating critical research and clinical insights from 2021 to 2024. The journal's commitment to open access means that groundbreaking studies are readily available to researchers, healthcare professionals, and students, fostering a collaborative approach to tackling global health challenges. As evidenced by its Q2 quartile ranking in the 2023 Scopus category of Infectious Diseases, and its impressive position within the top 25% of its field, Infectious Diseases Now serves as an essential resource for those involved in the study and management of infectious diseases. By publishing high-quality research, case studies, and reviews, the journal plays a pivotal role in advancing knowledge and improving patient care in this vital area of medicine.

GERMS is a multidisciplinary journal published by the EUROPEAN ACAD HIV-AIDS & INFECTIOUS DISEASES, dedicated to advancing knowledge in the fields of epidemiology, immunology, infectious diseases, and microbiology. Since its inception in 2011, the journal has provided a crucial platform for researchers and practitioners to share innovative studies, clinical findings, and public health insights, with an eye on improving health outcomes globally. With an ISSN of 2248-2997 and a consistent publication trajectory leading up to 2024, GERMS is recognized in the third quartile across several categories, reflecting its growing impact and relevance in the scientific community. Authors and readers benefit from a range of access options, fostering the dissemination of vital research findings. As a journal situated in Romania, it also addresses regional health challenges while contributing to the broader discourse on infectious diseases and public health. GERMS is not just a repository of knowledge, but a vital resource for those engaged in combating infectious diseases and promoting health equity.

EPIDEMIOLOGY AND INFECTION is a premier open-access journal published by Cambridge University Press, dedicated to advancing the field of epidemiology and infectious diseases. With an ISSN of 0950-2688 and E-ISSN of 1469-4409, this journal has been at the forefront of disseminating impactful research since its inception in 1970. As of 2023, it holds a prestigious Q2 ranking in both the fields of Epidemiology and Infectious Diseases, reflecting its significant contribution to these critical areas of study, with Scopus rankings placing it at #70 in Epidemiology and #163 in Infectious Diseases. The journal aims to publish high-quality, peer-reviewed studies that contribute to our understanding and management of infectious diseases globally. Operating under an open-access model since 2020, EPIDEMIOLOGY AND INFECTION ensures that research is accessible to a wide audience, fostering collaboration and innovation among researchers, professionals, and students alike. With a commitment to excellence, this journal is an essential resource for those looking to stay abreast of the latest developments in epidemiological research and infectious disease management.

Open Forum Infectious Diseases (ISSN: 2328-8957; E-ISSN: 2328-8957) is a leading open-access journal published by Oxford University Press, dedicated to advancing the field of infectious diseases. Since its inception in 2014, the journal has provided a platform for researchers to disseminate impactful findings in a rapidly evolving domain, achieving a remarkable Q1 ranking in both the Infectious Diseases and Oncology categories as of 2023. The journal encourages rigorous and innovative research, contributing significantly to global health discussions and informing best practices in clinical settings. As an open-access journal, it ensures that its content is accessible to a wide audience, fostering collaboration and knowledge sharing among researchers, professionals, and students alike. Positioned in the heart of the United States, Open Forum Infectious Diseases serves as a critical resource for the academic community, and its continued commitment to quality and relevance secures its status as an essential publication in the field.

Infectious Microbes & Diseases, published by Lippincott Williams & Wilkins, is a premier journal dedicated to the exploration and understanding of infectious diseases, microbiology, and epidemiology. With its focused scope and robust peer-review process, the journal aims to disseminate high-quality research that contributes to advancements in the field, making it an essential resource for researchers, healthcare professionals, and students alike. Established in 2019, it has quickly gained recognition, achieving a Q3 rating in categories such as Epidemiology, Infectious Diseases, and Medical Microbiology in 2023, and ranking in the top half of its field within Scopus metrics. Although currently offered as a subscription-based journal, Infectious Microbes & Diseases significantly enriches its disciplines by inviting innovative research and critical review articles, thus playing a vital role in combating the global challenges posed by infectious diseases.

Therapeutic Advances in Infectious Disease is a distinguished journal published by SAGE Publications Ltd, dedicated to advancing knowledge in the vital field of infectious diseases and pharmacology. With an impactful Open Access model since 2019, the journal facilitates unrestricted access to a wealth of high-quality research, enabling researchers, clinicians, and educators to stay at the forefront of infectious disease management and treatment. As a recognition of its contribution to the scientific community, the journal holds a prestigious Q1 quartile ranking in both Infectious Diseases and Medical Pharmacology as of 2023, underscoring its influence and relevance in these domains. The journal is positioned favorably within the Scopus rankings, with an impressive standing in the diverse categories of Medicine, emphasizing its commitment to disseminating innovative research. Through a rigorous peer-review process and a broad scope that covers therapeutic advancements, Therapeutic Advances in Infectious Disease serves as an essential resource for anyone involved in combating infectious diseases, offering insights that drive clinical applications and enhance patient care.

Journal of Infection and Public Health is a premier open-access journal published by ELSEVIER SCIENCE LONDON, dedicated to advancing knowledge in the fields of infectious diseases, public health, and environmental health. Since its inception in 2008, this esteemed journal has become a cornerstone of research dissemination, especially after transitioning to an open-access model in 2017, allowing wider accessibility to groundbreaking studies. With an impressive impact factor and ranking in the Q1 category for Infectious Diseases and Public Health as of 2023, the journal stands at the forefront of scientific inquiry, boasting a Scopus rank of #22 out of 665 in Public Health, underscoring its influence and reach in the academic community. Researchers, professionals, and students alike will find the journal's rich repository of peer-reviewed articles invaluable for ongoing education and practice in a rapidly evolving field. For contributing to the global understanding of health dynamics, Journal of Infection and Public Health is a vital resource, inviting scholars to explore, engage, and contribute to the crucial discussions shaping our world.

Welcome to the Journal of Microbiology Immunology and Infection, a premier academic publication established in 1998 and now proudly owned by Elsevier Taiwan. As an Open Access journal since 2016, it provides unrestricted access to groundbreaking research in the fields of immunology, microbiology, and infectious diseases, making it an essential resource for researchers, practitioners, and students alike. The journal holds impressive rankings, including Q1 status in categories such as Infectious Diseases and Microbiology (medical), and a notable 92nd percentile in its Scopus ranking for Medicine - Infectious Diseases. With a dedicated focus on advancing knowledge and fostering collaboration within the scientific community, the Journal of Microbiology Immunology and Infection is committed to publishing high-impact research that significantly influences practice and policy in healthcare and life sciences. The journal is also recognized for its contribution to the ongoing dialogue surrounding contemporary issues in immunology and infection, positioning it as a vital platform for scholarly exchange and innovation.